Pradaxa Lawsuits Move Forward, as Federal Litigation Schedules January Status Conference, Bernstein Liebhard LLP Reports
The Firm is evaluating Pradaxa lawsuits on behalf of individuals who suffered life-threatening episodes of internal bleeding, allegedly due to Pradaxa.
New York, New York (PRWEB) January 12, 2014
Thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) filed on behalf of individuals who suffered life-threatening episodes of internal bleeding, allegedly due to their use of the blood thinner, continue to move forward in U.S. District Court Southern District of Illinois, Bernstein Liebhard LLP reports. According to court documents, the proceeding's next telephonic Status Conference has been schedule for January 24, 2014 at 1:00 p.m. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“Our Firm continues to hear from individuals who allegedly suffered serious episodes of Pradaxa bleeding. We are pleased to see these lawsuits moving forward, and look forward to additional progress in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered serious internal bleeding while using this medication.
Pradaxa Bleeding Allegations
Court documents indicate that more than 2,070 Pradaxa lawsuits are currently pending in the Southern District of Illinois. Among other things, these lawsuits claim that Boehringer Ingelheim failed to warn doctors and patients that there existed no readily available antidote to reverse bleeding that sometimes occurs with Pradaxa.
The Institute for Safe Medicine Practices (ISMP) reported this October that Pradaxa had been named in more than 3,200 adverse event reports logged by the U.S Food & Drug Administration (FDA) in 2012. The incidents included 582 fatalities. By contrast, warfarin, a blood thinner that’s been on the market for decades, was the subject of just 861 reports, including 56 deaths.*
In December, the FDA announced that was planning a large scale assessment of Pradaxa bleeding rates. In a posting on an agency website, the FDA said the assessment will look at “selected safety outcomes in adults with atrial fibrillation who are new users of dabigatran or warfarin.”**
Individuals who used Pradaxa and allegedly suffered serious episodes of internal bleeding could be entitled to compensation for any injury-related damages they sustained. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013
**mini-sentinel.org/assessments/medical_events/details.aspx?ID=219, FDA, December 30, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11481007.htm